Is it ever appropriate to de-escalate regional nodal coverage in PMRT for patients with localized inflammatory breast cancer (IBC)?

At this time, I would still use full nodal coverage for all inflammatory breast cancers regardless of responses to neoadjuvant chemotherapy. I cover dissected and undissected axilla, SCV, and IMN.